Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
42
NUS Quote, Financials, Valuation and Earnings
Last price:
$6.82
Seasonality move
:
1.23%
Day range:
$6.55 - $6.83
52-week range:
$5.95 - $20.75
Dividend yield:
3.6%
P/E ratio:
--
P/S ratio:
0.19x
P/B ratio:
0.47x
Volume:
266.3K
Avg. volume:
808.3K
1-year change:
-65.56%
Market cap:
$331.1M
Revenue:
$2B
EPS (TTM):
-$2.07
Analysts' Opinion
-
Consensus RatingNu Skin Enterprises has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.92, Nu Skin Enterprises has an estimated upside of 3.85% from its current price of $6.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.75 representing 100% downside risk from its current price of $6.66.
Fair Value
-
According to the consensus of 3 analysts, Nu Skin Enterprises has 3.85% upside to fair value with a price target of $6.92 per share.
NUS vs. S&P 500
-
Over the past 5 trading days, Nu Skin Enterprises has underperformed the S&P 500 by -11.62% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nu Skin Enterprises does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nu Skin Enterprises revenues have been falling on a year-over-year basis for 13 quarters in a row. In the most recent quarter Nu Skin Enterprises reported revenues of $430.1M.
Earnings Growth
-
Nu Skin Enterprises earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Nu Skin Enterprises reported earnings per share of $0.17.
Enterprise value:
526.7M
EV / Invested capital:
0.46x
Price / LTM sales:
0.19x
EV / EBIT:
15.93x
EV / Revenue:
0.30x
PEG ratio (5yr expected):
--
EV / Free cash flow:
5.80x
Price / Operating cash flow:
3.64x
Enterprise value / EBITDA:
67.04x
Gross Profit (TTM):
$1.3B
Return On Assets:
-6.06%
Net Income Margin (TTM):
-5.81%
Return On Equity:
-13.41%
Return On Invested Capital:
-8.29%
Operating Margin:
4.24%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.4B | $2B | $1.8B | $498.8M | $430.1M | |
| Gross Profit | $1.7B | $1.4B | $1.3B | $292.3M | $301.5M | |
| Operating Income | $185.7M | $87.8M | $84M | -$26.4M | $18.2M | |
| EBITDA | $258.1M | $152.2M | $7.9M | -$8.7M | $37.1M | |
| Diluted EPS | $0.73 | $1.18 | -$2.07 | -$0.74 | $0.17 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $772.3M | $890.9M | $777.8M | $701.1M | $653.4M | |
| Total Assets | $1.8B | $2B | $1.8B | $1.8B | $1.6B | |
| Current Liabilities | $466.4M | $540.6M | $365.5M | $434M | $339.4M | |
| Total Liabilities | $989.2M | $1B | $921.2M | $970.9M | $876M | |
| Total Equity | $827.5M | $936.5M | $841.9M | $822.2M | $706.9M | |
| Total Debt | $342.7M | $388.6M | $424.8M | $502.9M | $433.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $192M | $90M | $140.1M | $51M | $31.4M | |
| Cash From Investing | -$69.3M | -$132.5M | -$39.7M | -$11.9M | -$6.5M | |
| Cash From Financing | -$84.6M | -$19.8M | -$109.8M | -$38.4M | -$28.8M | |
| Free Cash Flow | $128.5M | $38.1M | $90.7M | $39.1M | $22.8M | |
NUS
Sector
Market Cap
$331.1M
$339.9M
Price % of 52-Week High
32.1%
73.76%
Dividend Yield
3.6%
0%
Shareholder Yield
--
2.64%
1-Year Price Total Return
-65.56%
-13.42%
Beta (5-Year)
1.200
0.504
Dividend yield:
3.6%
Annualized payout:
$1.56
Payout ratio:
-27.34%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.01
200-day SMA
Sell
Level
$9.92
Bollinger Bands (100)
Sell
Level
6.35 - 8.87
Chaikin Money Flow
Buy
Level
25.7M
20-day SMA
Sell
Level
$7.36
Relative Strength Index (RSI14)
Sell
Level
38.28
ADX Line
Sell
Level
22.15
Williams %R
Buy
Level
-92.233
50-day SMA
Sell
Level
$6.97
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-31.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.4976)
Buy
CA Score
(Annual)
Level (0.011)
Sell
Beneish M-Score
(Annual)
Level (-2.135)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.0817)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
Stock Forecast FAQ
In the current month, NUS has received 0 Buy ratings 3 Hold ratings, and 0 Sell ratings. The NUS average analyst price target in the past 3 months is $6.92.
-
Where Will Nu Skin Enterprises Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nu Skin Enterprises share price will rise to $6.92 per share over the next 12 months.
-
What Do Analysts Say About Nu Skin Enterprises?
Analysts are divided on their view about Nu Skin Enterprises share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nu Skin Enterprises is a Sell and believe this share price will drop from its current level to $6.75.
-
What Is Nu Skin Enterprises's Price Target?
The price target for Nu Skin Enterprises over the next 1-year time period is forecast to be $6.92 according to 3 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is NUS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nu Skin Enterprises is a Hold. 3 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NUS?
You can purchase shares of Nu Skin Enterprises via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nu Skin Enterprises shares.
-
What Is The Nu Skin Enterprises Share Price Today?
Nu Skin Enterprises was last trading at $6.82 per share. This represents the most recent stock quote for Nu Skin Enterprises. Yesterday, Nu Skin Enterprises closed at $6.66 per share.
-
How To Buy Nu Skin Enterprises Stock Online?
In order to purchase Nu Skin Enterprises stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is up 0.98% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.38% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 1.42% over the past day.
